Advertisement
UK markets close in 8 hours 19 minutes
  • FTSE 100

    8,044.81
    0.00 (0.00%)
     
  • FTSE 250

    19,799.72
    0.00 (0.00%)
     
  • AIM

    754.87
    0.00 (0.00%)
     
  • GBP/EUR

    1.1632
    +0.0004 (+0.04%)
     
  • GBP/USD

    1.2439
    -0.0014 (-0.11%)
     
  • Bitcoin GBP

    53,710.22
    +289.65 (+0.54%)
     
  • CMC Crypto 200

    1,417.50
    -6.60 (-0.46%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.51
    +0.15 (+0.18%)
     
  • GOLD FUTURES

    2,337.70
    -4.40 (-0.19%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,203.80
    +374.87 (+2.23%)
     
  • DAX

    18,137.65
    +276.85 (+1.55%)
     
  • CAC 40

    8,105.78
    0.00 (0.00%)
     

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.